Superior Mesenteric Vein Stenosis Complicating Crohn's Disease
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Portal Vein Stenting for Jejunal Variceal Bleeding After Recurrence of Pancreatic Adenocarcinoma: a Case Report and Review of the Literature
Case Report Portal Vein Stenting for Jejunal Variceal Bleeding after Recurrence of Pancreatic Adenocarcinoma: A Case Report and Review of the Literature 1) Department of Radiology, Kyushu University Beppu Hospital, Japan 2) Department of Surgery, Kyushu University Beppu Hospital, Japan 3) Department of Clinical Radiology, Graduate School of Medical Science, Kyushu University, Japan Seiichiro Takao1), Masakazu Hirakawa1), Kazuki Takeishi2), Yushi Motomura1), Katsumi Sakamoto1), Hajime Otsu2), Yusuke Yonemura2), Koshi Mimori2), Kousei Ishigami3) Abstract A 73-year-old woman with portal vein stenosis caused by tumor recurrence after pancreatoduodenectomy was treated with stent placement without embolization of the jejunal varix. Anticoagulation therapy using heparin followed by rivaroxaban was administered after the procedure. She continued to receive systemic chemotherapy as an outpatient. Neither restenosis nor stent thrombosis was observed after 7 months. Based on the presented case and literature review, portal vein stenting is an effective treatment option for jejunal variceal bleeding caused by malignant portal venous stricture after pancreaticoduodenectomy. Antithrombotic therapy following portal venous stenting is required to prevent stent thrombosis in the majority of cases, al- though it has a risk of inducing recurrent variceal bleeding. Adjunctive jejunal variceal embolization can pos- sibly be omitted in selected cases to obtain sufficient portal-SMV flow reconstruction. Key words: Portal vein, Constriction, Stents (Interventional Radiology 2021; 6: 44-50) port describes a case of successful stenting for a patient Introduction with portal venous stenosis and bleeding from jejunal varices after pancreatoduodenectomy, along with the relevant Recurrent pancreatic cancer can cause portal venous literature. stenosis, resulting in symptoms of portal hypertension, such as hemorrhagic tendencies and liver dysfunction. -
Diagnosis and Management of Ectopic Varices
Gastrointest Interv 2012; 1:3–10 Contents lists available at SciVerse ScienceDirect Gastrointestinal Intervention journal homepage: www.gi-intervention.org Review Article Diagnosis and management of ectopic varices Nabeel M. Akhter, Ziv J. Haskal* abstract Ectopic varices are large portosystemic collaterals in locations other than the gastroesophageal region. They account for up to 5% of all variceal bleeding; however, hemorrhage can be massive with mortality reaching up to 40%. Given their sporadic nature, literature is limited to case reports, small case series and reviews, without guidelines on management. As the source of bleeding can be obscure, the physician managing such a patient needs to establish diagnosis early. Multislice computed tomography with contrast and reformatted images is a rapid and validated modality in establishing diagnosis. Further management is dictated by location, underlying cause of ectopic varices and available expertise. Therapeutic options may include double balloon enteroscopy, transcatheter embolization or sclerotherapy, with or without portosystemic decompression, i.e., transjugular intrahepatic portosystemic shunts. In this article we review the prevalence, etiopathogenesis, anatomy, presentation, and diagnosis of ectopic varices with emphasis on recent advances in management. Copyright Ó 2012, Society of Gastrointestinal Intervention. Published by Elsevier. All rights reserved. Keywords: Balloon-occluded retrograde transvenous obliteration, Ectopic varices, Portal hypertension, Percutaneous embolization, -
Umb 3 Lat Umb2'2006 Corectat3.Qxd
Archives of the Balkan Medical Union vol. 50, no. 3, pp. 379-385 Copyright © 2015 CELSIUS September 2015 REVIEW ETHIOPATHOGENIC CORRELATIONS AND TREATMENT MEANS IN UPPER NON-VARICOSE GASTROINTESTINAL BLEEDINGS C. BÃLÃLÃU1, R.V. SCÃUNAÆU2, I. MOTOFEI1, N. BACALBAÆA1, V. D. CONSTANTIN1, O.D. BÃLÃLÃU3, A. STÃNESCU3 1Department of General Surgery, University of Medicine “Carol Davila”, Emergency Universitary Hospital “St. Pantelimon”, Bucharest 2Department of General Surgery, University of Medicine “Carol Davila”, Colåea Clinical Hospital, Bucharest 3St. John Emergency Hospital, Bucur Maternity, Bucharest SUMMARY RÉSUMÉ Applying the scores according to the ethiopthogenesis of the upper Corrélations étiopathogéniques et modalités de traitement gastrointestinal bleeding. Influencing the medication and surgical dans les saignements gastro-intestinaux supérieurs de nature treatment according to prognosis. Development of a prognosis non-variqueuse score modified for assessing the need or not for admission of some patients belonging to different risk groups, performing endoscopy L’application des scores en fonction de l’éthiopthogenèse du saigne- or blood transfusions in patients with upper gastrointestinal ment gastro-intestinal supérieur. Influencer le médicament et le bleeding of non-varicose origin. Prospective study on patients with traitement chirurgical selon les prévisions. Le développement d'un upper non- varicose gastrointestinal bleeding, the group approxi- pronostic du score modifié afin d’évaluer la nécessité ou non de mation being made based on the retrospective data gathered from l'admission de certains patients appartenant à différents groupes de the Emergency Department statistics and compared to the Surgery risque, à l’endoscopie ou aux transfusions sanguines des patients and Gastroenterology Departments discharge documents. présentant un saignement gastro-intestinal supérieur d'origine non Key words: Upper gastrointestinal bleeding, ethiopathogenesis, variqueuse. -
Ministry of Education and Science of Ukraine Sumy State University 0
Ministry of Education and Science of Ukraine Sumy State University 0 Ministry of Education and Science of Ukraine Sumy State University SPLANCHNOLOGY, CARDIOVASCULAR AND IMMUNE SYSTEMS STUDY GUIDE Recommended by the Academic Council of Sumy State University Sumy Sumy State University 2016 1 УДК 611.1/.6+612.1+612.017.1](072) ББК 28.863.5я73 С72 Composite authors: V. I. Bumeister, Doctor of Biological Sciences, Professor; L. G. Sulim, Senior Lecturer; O. O. Prykhodko, Candidate of Medical Sciences, Assistant; O. S. Yarmolenko, Candidate of Medical Sciences, Assistant Reviewers: I. L. Kolisnyk – Associate Professor Ph. D., Kharkiv National Medical University; M. V. Pogorelov – Doctor of Medical Sciences, Sumy State University Recommended for publication by Academic Council of Sumy State University as а study guide (minutes № 5 of 10.11.2016) Splanchnology Cardiovascular and Immune Systems : study guide / С72 V. I. Bumeister, L. G. Sulim, O. O. Prykhodko, O. S. Yarmolenko. – Sumy : Sumy State University, 2016. – 253 p. This manual is intended for the students of medical higher educational institutions of IV accreditation level who study Human Anatomy in the English language. Посібник рекомендований для студентів вищих медичних навчальних закладів IV рівня акредитації, які вивчають анатомію людини англійською мовою. УДК 611.1/.6+612.1+612.017.1](072) ББК 28.863.5я73 © Bumeister V. I., Sulim L G., Prykhodko О. O., Yarmolenko O. S., 2016 © Sumy State University, 2016 2 Hippocratic Oath «Ὄμνυμι Ἀπόλλωνα ἰητρὸν, καὶ Ἀσκληπιὸν, καὶ Ὑγείαν, καὶ Πανάκειαν, καὶ θεοὺς πάντας τε καὶ πάσας, ἵστορας ποιεύμενος, ἐπιτελέα ποιήσειν κατὰ δύναμιν καὶ κρίσιν ἐμὴν ὅρκον τόνδε καὶ ξυγγραφὴν τήνδε. -
Statistical Analysis Plan
Cover Page for Statistical Analysis Plan Sponsor name: Novo Nordisk A/S NCT number NCT03061214 Sponsor trial ID: NN9535-4114 Official title of study: SUSTAINTM CHINA - Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Document date: 22 August 2019 Semaglutide s.c (Ozempic®) Date: 22 August 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL Clinical Trial Report Status: Final Appendix 16.1.9 16.1.9 Documentation of statistical methods List of contents Statistical analysis plan...................................................................................................................... /LQN Statistical documentation................................................................................................................... /LQN Redacted VWDWLVWLFDODQDO\VLVSODQ Includes redaction of personal identifiable information only. Statistical Analysis Plan Date: 28 May 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL UTN:U1111-1149-0432 Status: Final EudraCT No.:NA Page: 1 of 30 Statistical Analysis Plan Trial ID: NN9535-4114 Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Author Biostatistics Semaglutide s.c. This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.This -
A Phase 3 Multicenter Study of the Long-Term Safety and Tolerability Of
A Phase 3 Multicenter Study of the Long-term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study) Unique Protocol ID: ALK5461-208 NCT Number: NCT02141399 EudraCT Number: 2014-000380-41 Date of Statistical Analysis 15 September 2017 Plan: STATISTICAL ANALYSIS PLAN PHASE III ALK5461-208 A Phase 3 Multicenter Study of the Long-term Safety and Study Title: Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study) Document Status: Final Document Date: 15 September 2017 Based on: Study protocol amendment 3 (dated 03 March 2016) Study protocol amendment 2 (dated 12 May 2015) Study protocol amendment 1 (dated 17 April 2014) Original study protocol (dated 16 December 2013) Sponsor: Alkermes, Inc. 852 Winter Street Waltham, MA 02451 USA CONFIDENTIAL Information and data in this document contain trade secrets and privileged or confidential information, which is the property of Alkermes, Inc. No person is authorized to make it public without the written permission of Alkermes, Inc. These restrictions or disclosures will apply equally to all future information supplied to you that is indicated as privileged or confidential. This study is being conducted in compliance with good clinical practice, including the archiving of essential documents. Alkermes, Inc. ALKS 5461 CONFIDENTIAL SAP-ALK5461-208 TABLE OF CONTENTS LIST OF ABBREVIATIONS ..........................................................................................................5 1. INTRODUCTION ........................................................................................................7 1.1. Study Objectives ...........................................................................................................7 1.2. Summary of the Study Design and Schedule of Assessments ......................................7 1.3. -
Descriptive Anatomy of Hepatic and Portal Veins with Special Reference
Brazilian Journal of Poultry Science Revista Brasileira de Ciência Avícola Descriptive Anatomy of Hepatic and Portal Veins ISSN 1516-635X 2019 / v.21 / n.2 / 001-012 with Special Reference to Biliary Duct System in Broiler Chickens (Gallus gallus domesticus): http://dx.doi.org/10.1590/1806-9061-2019-0980 A Recent Illustration Original Article Author(s) ABSTRACT Maher MAI https://orcid.org/0000-0002-7040-7813 Chickens have a great participation in meat and egg production. The anatomical scientific data of poultry is important to support the recent researches either for illustrations in academic studies or clinically in diagnosis and treatment of some poultry nutritional diseases. The current investigation was performed on twenty broiler chickens of both sexes. The chickens were anaesthetized, slaughtered then the venous system was flushed with a normal saline to anatomically investigate the distribution of hepatic portal veins both intra and extrahepatic, as well as the hepatic venous and biliary duct systems. The fowl had two hepatic portal veins draining the gastrointestinal tract with its associated organs as spleen and pancreas. The left hepatic portal vein was small, restricted to a limited portion of left hepatic lobe and had been constituted by five main venous tributaries draining the proventriculus, gizzard and pylorus, while the right hepatic portal vein was the largest, receiving the proventriculosplenic, gastropancreaticoduodenal and common mesenteric veins then piercing the right hepatic lobe to be distributed in both hepatic segments through right and left divisions. The fowl has two hepatic portal veins differed in size and distribution. A characteristic imaginary trapezoid shape was formed by some tributaries draining the caudoventral part of the gizzard. -
A Rare Case of Jejunal Arterio-Venous Fistula
© Springer ScienceϩBusiness Media, Inc., 2004 Cardiovasc Intervent Radiol (2004) 27:671–674 CardioVascular Published Online: 12 August 2004 DOI: 10.1007/s00270-004-0101-x and Interventional Radiology A Rare Case of Jejunal Arterio-Venous Fistula: Treatment with Superselective Catheter Embolization with a Tracker-18 Catheter and Microcoils Martin J. Sonnenschein, Suzanne E. Anderson, Steven Lourens, Juergen Triller Department of Diagnostic Radiology, Inselspital Bern, University of Berne, Freiburgstrasse 10, 3010, Berne, Switzerland Abstract jejunal arteries frequently manifest with isolated signs such as bleeding, abdominal pain, diarrhea, weight loss and a steal phe- Arterio-venous fistulas may develop spontaneously, following nomenon, suggesting that only a segment of the portal venous trauma or infection, or be iatrogenic in nature. We present a rare system (segmental portal hypertension) is involved [1]. The aim of case of a jejunal arterio- venous fistula in a 35-year-old man with a patient management is treatment of the underlying cause to prevent history of pancreatic head resection that had been performed two the development of portal hypertension complications such as years previously because of chronic pancreatitis. The patient was variceal hemorrhage and ascites. admitted with acute upper abdominal pain, vomiting and an ab- dominal machinery-type bruit. The diagnosis of a jejunal arterio- Case Report venous fistula was established by MR imaging. Transfemoral A 35-year-old male presented with upper abdominal pain and vomiting. angiography was performed to assess the possibility of catheter Significantly, 2 years ago the patient had an episode of chronic pancreatitis, embolization. The angiographic study revealed a small aneurysm of which was treated surgically by partial pancreatectomy. -
Acr–Sir–Spr Practice Parameter for the Creation of a Transjugular Intrahepatic Portosystemic Shunt (Tips)
The American College of Radiology, with more than 30,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study the socioeconomic aspects of the practice of radiology, and encourage continuing education for radiologists, radiation oncologists, medical physicists, and persons practicing in allied professional fields. The American College of Radiology will periodically define new practice parameters and technical standards for radiologic practice to help advance the science of radiology and to improve the quality of service to patients throughout the United States. Existing practice parameters and technical standards will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated. Each practice parameter and technical standard, representing a policy statement by the College, has undergone a thorough consensus process in which it has been subjected to extensive review and approval. The practice parameters and technical standards recognize that the safe and effective use of diagnostic and therapeutic radiology requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice parameter and technical standard by those entities not providing these services is not authorized. Revised 2017 (Resolution 15)* ACR–SIR–SPR PRACTICE PARAMETER FOR THE CREATION OF A TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) PREAMBLE This document is an educational tool designed to assist practitioners in providing appropriate radiologic care for patients. Practice Parameters and Technical Standards are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care1. -
Vascular Complications of Pancreatitis: Role of Interventional Therapy Jaideep U
Review Article http://dx.doi.org/10.3348/kjr.2012.13.S1.S45 pISSN 1229-6929 · eISSN 2005-8330 Korean J Radiol 2012;13(S1):S45-S55 Vascular Complications of Pancreatitis: Role of Interventional Therapy Jaideep U. Barge, MD1, Jorge E. Lopera, MD, FSIR2 1Diagnostic and Interventional Radiology at University of Texas Health Science Center at San Antonio, San Antonio, Tx 78249, USA; 2Vascular and Interventional Radiology at University of Texas Health Science Center at San Antonio, San Antonio, Tx 78249, USA Major vascular complications related to pancreatitis can cause life-threatening hemorrhage and have to be dealt with as an emergency, utilizing a multidisciplinary approach of angiography, endoscopy or surgery. These may occur secondary to direct vascular injuries, which result in the formation of splanchnic pseudoaneurysms, gastrointestinal etiologies such as peptic ulcer disease and gastroesophageal varices, and post-operative bleeding related to pancreatic surgery. In this review article, we discuss the pathophysiologic mechanisms, diagnostic modalities, and treatment of pancreatic vascular complications, with a focus on the role of minimally-invasive interventional therapies such as angioembolization, endovascular stenting, and ultrasound-guided percutaneous thrombin injection in their management. Index terms: Pseudoaneurysm; Pancreatitis; Hemorrhage; Vascular complications; Embolization; Stenting INTRODUCTION pancreatitis occur with a frequency of 1.2-14%, with a greater incidence seen in chronic pancreatitis (7-10%) than It has been estimated that there are more than 210000 acute pancreatitis (1-6%) (4, 5). The overall mortality rate admissions for acute pancreatitis and more than 56000 due to hemorrhage in acute pancreatitis has been reported hospitalizations for chronic pancreatitis in the United to reach ranges as high as 34-52%, and is significantly States each year (1). -
Scientific Abstracts
North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting November 1 - 4, 2017 Las Vegas, NV Scientific Abstracts Vol. 65, Supplement 2, November 2017 S1 POSTER SESSION I Thursday, November 2 5:00pm – 7:00pm *Posters of Distinction ENDOSCOPY/QI/EDUCATION 3 IMPROVING QUALITY AND UTILIZATION OF ANTI-TNF POST-INDUCTION THERAPEUTIC DRUG MONITORING. Amy Peasley, Emily Homan, Amy Donegan, Ross Maltz, Jennifer Dotson, Wallace Crandall, Brendan Boyle. Gastroenterology, Nationwide Children’s Hospital, Columbus, OH Background: Anti-tumor necrosis factor (TNF) therapy has revolutionized the care of pediatric patients with moderate to severe Crohn’s disease and ulcerative colitis. However, an estimated 40% of patients who initially respond to an anti-TNF will lose response within the first 12 months of initiation. Loss of response can have significant clinical consequences as alternative medical therapies after failing an anti-TNF medication are limited. Because of the high rate of loss of response and the limited treatment options available to these patients, a focus upon individualized care and optimization of anti-TNF therapy through therapeutic drug monitoring (TDM) has continued to grow. TDM ensures adequate serum drug levels in order to minimize antibody formation and maintain disease control. Detectable serum drug levels have been associated with higher rates of clinical remission, lower C-reactive protein, and endoscopic healing. Proactive TDM has been associated with greater drug durability, reduced formation of antibodies, and reduced risk of IBD-related surgery and hospitalization. We aim to describe the quality improvement (QI) methods used at our institution to improve post-induction TDM in children initiating anti-TNF therapy, and to optimize our use of these medications through dose adjustments. -
Back Matter 893-906.Pdf
Index A Ϫ Widmark’s formula 61 Angiography 178, 252, 367 Aspergillosis 507 Aagenaes type 233, 665 Alcohol dehydrogenase 62, 94, Angiolipoma 760 AST (GOT) 96 Abdominal baldness 80, 86 523 Angiomyolipoma 760 Asterixis 274 Abdominal wall varices 256 Alcohol injection, percutane- Angiosarcoma 793 Asteroid bodies 764 Abdominoscopy 149 ous 784, 801 Anorectal varices 256 Atransferrinaemia 618 Abetalipoproteinaemia 599 Alcoholic fatty liver 529 Antibiogram 304 Atrial natriuretic factor 293 Acamprosat 536 Alcoholic foamy degeneration Antibodies 117, 118, 237, 552, Atrophy, liver 78, 377 Acanthosis nigricans 619 530 679 Atrophy, testicular 86 Ϫ Accessory lobe 15 Alcoholic hyaline 525 antihistone 121, 524, 619 Australian antigen 113, 414 Ϫ Aceruloplasminaemia 618 Alcoholic liver disease 520 antinuclear 118, 657, 679 Autoimmune cholangitis 659 Ϫ Ϫ Ϫ Acetaldehyde 64 clinical features 529 antiribosomal P 654 morphology 660 Ϫ Ϫ Ϫ Acetic acid injection 784 diagnostic markers 534 granulocytes 121, 657 therapy 660 Ϫ Ϫ Acholic stool 240, 420 morphology 524 liver-kidney microsomes Autoimmune hepatitis 678 Ϫ Ϫ Aciclovir 465, 855 pathogenesis 527 119, 679 aetiopathogenesis 678 Ϫ Ϫ Ϫ Acid-base metabolism 59 therapy 536 liver membrane 119, 679 morphology 682 Ϫ Ϫ Acidophilic bodies 400 Alcoholism 521 mitochondria 120, 644 therapy 684 Ϫ Ϫ Acinus 9, 10, 22, 23 diagnostic markers 534 smooth muscle 117, 679 Autoimmune polyendocrine Ϫ Ϫ Acrodermatitis papulosa 84 physical dependence 520 soluble liver protein 120, syndrome 681 Ϫ Actin filament 27 psychological dependence